Alzheimer’s (Alnylam)

Enrolling Now
Study Information

A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacodynamics of Intrathecally Administered ALN-APP in Patients with Cerebral Amyloid Angiopathy (CAA).

Apply to Participate

If you are interested in participating in this study, please complete the following preliminary qualification form.

We will follow-up with you after we have received your submission.

"*" indicates required fields

General Information

Name*
ZIP / Postal Code*

Preferences

Email Opt-In*
SMS/Text Opt-In*
This field is for validation purposes and should be left unchanged.